Does Use of the Voy Program Improve Weight Loss Percentage and Other Health Outcomes in a Population Already Taking GLP/GIP-1RA Medication?
NCT ID: NCT06710587
Last Updated: 2024-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
470 participants
INTERVENTIONAL
2025-01-02
2027-04-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
If an eligible participant consents to take part in the trial, they will be randomly allocated into one of the two trial groups. One group will continue with the standard pathway for GLP/GIP-1RA as part of their usual care for weight loss, while the other group will utilise the Voy Program in addition to the standard pathway.
In the intervention group, the Voy Program will include personalised sessions with a qualified coach as well as access to resources including managing nutrition and movement. The frequency of the coaching sessions will be led by the participant but will normally start fortnightly.
All participants will be enrolled in the trial for 12 months and will be asked to complete questionnaires on a monthly and quarterly basis.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Screening, informed consent and eligibility assessments will occur online. Participants in the intervention group will receive coaching sessions via video and phone calls with a qualified coach. These sessions will be participant led but will normally initially occur fortnightly. Participants in the intervention arm will also have access to all available features in the Voy app, which is used to book coaching sessions and also includes content around nutrition and exercise management, weight progress tracking, and an AI-powered meal analysis tool to support behavioural changes. Participants will be expected to complete surveys monthly. Participants will enter data directly into the trial web platform, EDC platform or the sponsors platform (Voy). Participation in the initial trial is expected to last approximately 12 months, with optional long term follow-up continuing for an additional 12 months (24 months total).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control - Standard Pathway
Standard GLP/GIP-1RA pathway as offered by Voy as part of participants usual care for weight loss
No interventions assigned to this group
Intervention - Standard Pathway + Voy Program
Standard GLP/GIP-1RA pathway as offered by Voy as part of participants usual care for weight loss + Voy Program - coaching and access to the Voy app to support behavioural changes
Voy Program
Voy Program - coaching and access to the Voy app to support behavioural changes
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Voy Program
Voy Program - coaching and access to the Voy app to support behavioural changes
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. BMI≥30,
a. Or BMI≥27 with any of the following comorbidities as diagnosed by a Doctor:
* High blood pressure
* High cholesterol
* Obstructive sleep apnoea
* Erectile dysfunction
* Asthma
* Osteoarthritis
* Chronic back pain
* PCOS
* Fatty liver disease
3. Approved for the standard GLP/GIP-1RA pathway by Voy as part of usual care for weight loss.
4. People who use either an iOS or Android smartphone using operating system iOS 16 or Android 8 or later.
5. Agree to not use another intervention for weight loss for the duration of the trial.
* Other diet specific interventions such as meal replacement shakes.
* Over the counter medication / supplements such as appetite suppressants, thermogenics, herbal supplements.
* Any other medicated weight loss program.
* Structured weight loss programs such as Weight Watchers, Noom, Second Nature.
* Non-surgical medical weight management such as lipotropic injections and metabolic enhancers.
* Surgical interventions such as a gastric bypass, banding, or other bariatric surgery
* Other personalised nutrition programmes, such as ZOE
6. Able and willing to provide Informed Consent and adhere to trial procedures.
Exclusion Criteria
2. Known diabetes mellitus (Type 1 or 2) or thyroid disease.
3. Previous surgery or endoscopic intervention for obesity, or planned surgery or endoscopic intervention for obesity in the next 12 months.
4. Lost ≥ 5kg in the last 3 months intentionally or otherwise.
5. Currently using other weight loss medications, or use of other weight loss medications in the past 6 months.
6. Currently using medications that cause weight gain, including systemic steroids, or used such medications in the past 6 months.
7. Severe anxiety or depression (either PHQ-9 \>15 or GAD7 \>10).
8. Severe eating disorder (Binge eating scale ≥27).
9. Participation in another interventional clinical study or use of investigational drugs in the last 6 months.
10. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lindus Health
INDUSTRY
Menwell Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carel Le Roux
Role: PRINCIPAL_INVESTIGATOR
Ulster University
Werd Al-Najim
Role: PRINCIPAL_INVESTIGATOR
Ulster University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
350648
Identifier Type: OTHER
Identifier Source: secondary_id
LH-MAN-01
Identifier Type: -
Identifier Source: org_study_id